DailyWealth Investment Newsletter  

About DailyWealth Premium Content DailyWealth Archive
DailyWealth Investment Newsletter DailyWealth Contributors DailyWealth Resources DailyWealth Market Window
 
DailyWealth Print Edition Print Edition | Sponsored Link:
True Wealth Login

Our Secret Weapon: What Goes Up When Nothing Else Will
By Dr. Steve Sjuggerud
March 7, 2007

"I took Steve's advice and increased our cash position... last Monday I sold two riskier emerging market positions and immediately rolled into Steve's recommended Access Flex Bear High Yield Fund (AFBIX). Of course, last Tuesday, as Steve would say, things went to 'less perfect.' ... I can't thank you and your team enough for being really smart and helping us keep our portfolio on course... Great Job!" – True Wealth subscriber Ralph.

Last week, everything went down. But AFBIX went up.

In the February issue of True Wealth, I encouraged readers to buy shares of AFBIX. I called it a "direct bet on things simply going from perfect to less perfect."

Ralph took our advice... and his timing was perfect. But what's AFBIX?

Buying AFBIX, I told my subscribers, is "like we're buying hurricane insurance in a place that hasn't seen a big storm in years – but sits right in hurricane alley."

AFBIX is a special kind of fund that tracks the cost of insurance. Only it's not weather insurance – it's financial insurance. The kind large investors buy to protect themselves against a catastrophic hit to their portfolios.

Of course, the cost of insurance is the cheapest when you haven't seen a big storm in a while. And the world of finance was placid as a produce market in the second half of 2006.

As the stock market (the black line in the chart below) went higher and higher in late 2006, the cost of insurance against financial default (the blue line) went lower and lower (it's upside-down on the chart, so you can see how it's tracked the stock market).

AFBIX tracks that blue line. The cost of insurance, as you can see, got incredibly cheap in January. I posed the question to subscribers in my February issue, "How much lower can the price of insurance go?"

"Since nobody believes anything can go wrong, the price of insurance is incredibly cheap... It's not a question of whether a hurricane will hit. It is a question of how severe the damage will be this time around. We want to buy AFBIX low (now), and sell high (in the midst of the next recession). We will make good money – 20% to 50% depending on the severity of the recession – with very little risk.

"Even better, this fund can do well regardless of what happens in the stock market. With limited downside, and significant upside, AFBIX is a pitch to swing at."

Ralph's timing was perfect (better than mine, actually!). It turned out, the price of insurance wasn't going any lower... now that stocks are dropping and investors are scared to death, AFBIX is jumping up:

While this looks like a big move on the chart, percentage-wise, it's not that big at all. There's still plenty room to run. The cost of financial insurance can easily keep going up.

In short, when everyone gets scared and nothing else works, AFBIX will. Nice work, Ralph... and thanks for subscribing.

To learn more about AFBIX, visit www.accesshighyield.com – or better yet, become a subscriber to True Wealth and read all about it.

I pulled the chart of "financial insurance" from my friend Jason Goepfert's excellent website, www.sentimentrader.com. I've been a subscriber for years.

Good investing,

Steve

Editor's note: Steve Sjuggerud is a regular contributor to DailyWealth, a free investment newsletter focused on the world's best contrarian opportunities. We write with a simple belief in mind: You don't have to take big risks to make big money with your investments.

Sign up today to read more investment ideas from Steve Sjuggerud.

Email a Friend

Delicious
Reddit

Digg

RSS

EMERGING MARKETS TAKE A BEATING... DID YOU GET OUT?

It was the most important chart we could have showed you a month ago...

In our February 16 issue, we published a chart showing how emerging-market stocks were as expensive as they had ever been on a price-to-book basis. Meanwhile, close to $200 billion flowed into risky markets like Brazil, Russia, and Indonesia in 2006.

We couldn't have been clearer... that expensive stocks and record speculation always makes for a painful ending. Emerging markets are getting killed now.

For a picture of the rout, let's look at one of the most popular emerging-market equities, the iShares Emerging Markets Fund. This $12 billion ETF contains the most popular foreign stocks in the world... firms like Gazprom (Russian oil), Samsung (Korean electronics), Infosys (Indian outsourcing), and China Mobile (Chinese telecom).

We're sure emerging markets will be great values again someday... but we'll have to see more "froth" boiled off before we're buyers. This decline has further to run.

Make no bones about it, bum knees and worn-out hips mean good business for orthopedic-implant manufacturers.

Efforts by the main players in the industry to make longer-lasting, higher-margin products – coupled with the global demographic trend of an aging and plumper population – make the orthopedics sector a robust investment over the long term.

"The story is simple: We're getting older, living longer and requiring more reconstructive knees and hips," says Robert Sellar, head of U.S. equities in Philadelphia for Aberdeen Asset Management PLC, which has $148 billion in assets.

Industry projections point to greater demand for years to come, particularly from people under the age of 65. The number of knee replacements – which require less-invasive surgical techniques and shorter recovery periods in the hospital – is expected to jump more than seven times to 3.5 million by 2030, while state-of-the-art hip replacements will rise by 174%, according to a 2006 study headed by Exponent Inc.

– Wall Street Journal

The U.S. health care system — touted as providing the best medical care in the world — is becoming more precarious to most Americans, who are rattled by rising costs, questions about quality and fears about the future.

An overwhelming 80% of respondents said they were dissatisfied with the total tab the nation spends on health care, estimated to hit $2.2 trillion, or $7,129 a person, this year.

– USA TODAY

DailyWealth is Dr. Steve Sjuggerud's FREE daily e-Letter...

To receive Steve's best investment ideas each month, try a No-Cost, No-Risk trial subscription to his monthly advisory, True Wealth.

Click here to get started.

Home | About DailyWealth | Premium Content | DailyWealth Archive | Contributors
DailyWealth Resources | Research Reports | Privacy Policy

Customer Service: 1-888-261-2693 – Copyright 2008 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202